The Volt PFA system. [Image courtesy of Abbott] Abbott (NYSE: ABT) + announced it received CE mark approval in Europe for its ...

Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

With PFA becoming physicians’ preferred ablation method for treating AFib, Abbott is pushing to catch up with rival systems ...

Though late to the party compared to other industry leaders, Abbott joins a pulsed field ablation market poised for ...

(RTTNews) - Abbott (ABT) Thursday announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark ...

Abbott (ABT) announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation. With the ...

Abbott (NYSE: ABT), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $219.58 billion, has received CE Mark approval for its Volt PFA System ...

Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy ...

ABBOTT PARK, Ill. - Abbott (NYSE: ABT), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $219.58 billion, has received CE Mark approval for its Volt ...